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Abstract 
Purpose: The aim of the RUBY study was to evaluate novel candidate biomarkers to enable prediction of persistence 
of renal dysfunction as well as further understand potential mechanisms of kidney tissue damage and repair in acute 
kidney injury (AKI).
Methods: The RUBY study was a multi‑center international prospective observational study to identify biomarkers of 
the persistence of stage 3 AKI as defined by the KDIGO criteria. Patients in the intensive care unit (ICU) with moderate 
or severe AKI (KDIGO stage 2 or 3) were enrolled. Patients were to be enrolled within 36 h of meeting KDIGO stage 2 
criteria. The primary study endpoint was the development of persistent severe AKI (KDIGO stage 3) lasting for 72 h or 
more (NCT01868724).
Results: 364 patients were enrolled of whom 331 (91%) were available for the primary analysis. One hundred ten 
(33%) of the analysis cohort met the primary endpoint of persistent stage 3 AKI. Of the biomarkers tested in this study, 
urinary C–C motif chemokine ligand 14 (CCL14) was the most predictive of persistent stage 3 AKI with an area under 
the receiver operating characteristic curve (AUC) (95% CI) of 0.83 (0.78–0.87). This AUC was significantly greater than 
values for other biomarkers associated with AKI including urinary KIM‑1, plasma cystatin C, and urinary NGAL, none of 
which achieved an AUC > 0.75.
Conclusion: Elevated urinary CCL14 predicts persistent AKI in a large heterogeneous cohort of critically ill patients 
with severe AKI. The discovery of CCL14 as a predictor of persistent AKI and thus, renal non‑recovery, is novel and 
could help identify new therapeutic approaches to AKI.
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Introduction
Acute kidney injury (AKI) is a global problem affect-
ing more than 10% of all hospitalized patients and 
approaching two-thirds of those admitted to intensive 
care units, with survival related not only to the sever-
ity, but also to the duration of renal dysfunction [1–3]. 
Recent evidence suggests that two-thirds of patients 
with AKI resolve their renal dysfunction within 
3–7 days whereas those who persist have dramatically 
reduced survival over the following year [4]. Persis-
tence of AKI is of grave importance in that it increases 
an individual’s risk of developing chronic kidney dis-
ease (CKD)  and the consequences thereof [5]. This 
link between AKI and CKD has been established over 
the last decade and specific recommendations for the 
management of patients with AKI have been proposed 
in order to potentially influence this transition [5, 6]. 
It follows that early identification of individuals at risk 
of persistent AKI would enable appropriate delivery 
of these proposed interventions, but also may identify 
individuals where newer therapies to attenuate AKI 
could be targeted.
Not only is persistence of AKI relevant to longer 
term outcomes, clinical decision-making is also criti-
cally affected by physician expectations surrounding 
renal recovery and the decision of when to initiate renal 
replacement therapy (RRT). Currently this is almost 
totally dependent on clinical expectations as to the like-
lihood of recovery with no available diagnostics to aid 
this decision process. As such, significant controversy 
exists around the timing of RRT with studies showing 
that some patients can benefit from the earlier initia-
tion of RRT, while other studies demonstrate that some 
individuals receive RRT who may not require such treat-
ment as they will recover renal function soon [7, 8]. Early 
and reliable identification of those who will recover renal 
function may enable a more stratified approach to man-
agement, thus avoiding the incumbent risks of extracor-
poreal therapy.
Of equal or even greater importance is that the mech-
anisms responsible for recovery from AKI are incom-
pletely understood. Recovery following AKI involves 
dedifferentiation and proliferation of viable cells which 
then re-epithelialize the nephron. Failure to regener-
ate lost cells results in a maladaptive repair and fibrosis 
[9]. Key mechanisms and triggers for these processes are 
largely unknown.
In order to find potential markers for persistent AKI, 
both as candidates for diagnostic testing as well as poten-
tial drug targets, we tested novel candidate biomarkers in 
an international multi-center prospective study to pre-
dict persistence of AKI.
Methods
Study design
The RUBY study is an international prospective obser-
vational study aimed at identifying biomarkers associ-
ated with the persistence of stage 3 AKI as defined by 
the KDIGO criteria [10]. Adult patients in the intensive 
care unit (ICU) with moderate or severe AKI (stage 2 
or 3) and an indwelling urinary catheter were enrolled 
from June 2013 through May 2014. Both serum creati-
nine and urine output criteria were used to determine 
KDIGO AKI stage [10]. Patients were enrolled within 
36 h of meeting the KDIGO criteria as determined by the 
investigator based on serum creatinine and urine output 
data available at the time of enrollment. Any patients 
later determined not to be at stage 2 or 3 at enrollment 
by retrospective analysis were retained in the primary 
analysis cohort based on the intent to diagnose princi-
ple [11]. Patients were excluded if they had a prior kid-
ney transplant, were receiving, or were in imminent need 
of RRT, were receiving comfort measures only, or had 
known infection with human immunodeficiency virus or 
active hepatitis. Written informed consent was provided 
by all patients or their legally authorized representatives 
prior to enrollment. The RUBY study was approved by 
the Western Institutional Review Board (Puyallup, WA) 
and by individual investigational review boards or ethics 
committees as required by each enrolling site.
The primary study endpoint was the development of 
persistent, severe AKI (stage 3), lasting for 72 h or more 
given that evidence demonstrates that the short and long-
term risk of death or need for RRT is greatest for patients 
who persist with AKI for longer than 3 days [4]. This pri-
mary endpoint is consistent with more recent studies on 
initiation of RRT which specified 72 h of oliguria as crite-
rion for initiation of treatment [12].
For the purposes of determining the primary end-
point, each patient’s baseline serum creatinine was 
retrospectively adjudicated by a physician blinded to 
biomarker data based on serum creatinine data collected 
from the medical record from 6  months prior to enroll-
ment through 3 months after enrollment. Patients not at 
stage 3 AKI at enrollment were required to reach stage 
3 within 48 h and then persist in stage 3 AKI for at least 
72  h to be considered endpoint positive. Patients who 
Take‑Home Message 
This manuscript is the first report on a new biomarker, urinary 
chemokine ligand CCL14, which is a predictor of persistent stage 
3 AKI. CCL14 has never been identified in the pathobiology of AKI 
before. The role of this chemokine is entirely consistent with what 
is known about the development of renal damage and repair, in 
particular macrophage trafficking and subsequent fibrosis.
had a maximum AKI stage of 3 and died within 48 h of 
enrollment were also considered endpoint positive. Addi-
tionally, patients with stage 3 AKI who failed to achieve 
72 consecutive hours due to initiation of RRT or death 
were considered endpoint positive (Fig. 1). The secondary 
endpoints were the composite of RRT initiation or death 
within 90  days and major adverse kidney events at 90 
(± 7) days  (MAKE90) [13]. MAKE was defined as the com-
posite of ≥ 25% loss in estimated glomerular filtration rate 
(eGFR), dialysis, or death. Estimated GFR was calculated 
from serum creatinine using the MDRD equation.
Sample and data collection
Blood and urine samples were collected at enrollment 
and centrifuged. Plasma (EDTA), serum, and urine 
supernatants were frozen within 2 h of sample collection, 
stored at ≤ −  70  °C, and thawed immediately prior to 
analysis. Patient data abstracted from the medical record 
included demographics, medical history, APACHE III 
variables, reason for admission, hourly urine output from 
the day prior to enrollment through study day 7, as well 
as serum creatinine, RRT, and death through 90  days 
after enrollment. Telephone follow-up was conducted at 
90 (± 7) days to provide additional data for the  MAKE90 
endpoint.
Biomarker identification and testing
Potential candidate biomarkers from proteins associated 
with apoptosis, necrosis, endothelial injury, cell–cell 
and cell–matrix adhesion, cytoprotection, oxidative 
processes, cell-cycle regulation, inflammation, tubu-
lar injury, immune function, and fibrosis were selected 
for biologic plausibility based on previously described 
methods [14]. The aim was to determine whether the 
candidate proteins could aid in risk assessment for per-
sistence of renal dysfunction as well as contribute to the 
understanding behind the mechanisms of renal tissue 
damage and repair. A broad set of potential biomark-
ers were assessed focused on potential mechanisms of 
action as opposed to relying on defined AKI biomarkers 
alone.
Biomarkers were measured in urine and/or plasma at 
Astute Medical (San Diego, CA, USA) by technicians 
blinded to clinical data. Plasma and urinary NGAL were 
measured by enzyme-linked immunosorbent assay (Bio-
porto, Copenhagen, Denmark). The combination of 
tissue inhibitor of metallproteinases-2 (TIMP-2) and 
insulin-like growth factor-binding protein 7 (IGFBP7) 
was measured in urine with the NEPHROCHECK 
CCL14 Test (Astute Medical) as was the final analy-
sis of urinary C–C motif chemokine ligand 14 (CCL14) 
using a prototype clinical immunoassay. Proenkepha-
lin 119–159 was measured in plasma with sphingotest 
pro-ENK (sphingotec GmBH, Hennigsdorf, Germany). 
Other previously described biomarkers of AKI were 
measured on the Luminex 200 platform (Luminex, Aus-
tin, TX, USA) either with commercial kits from EMD 
Millipore (Billerica, MA, USA) [urinary chitinase-3-like 
No persistent severe AKI
N = 221 (67%)
Persistent severe AKI
N = 110 (33%)
Ruby Enrollment
21 sites
(12 United States, 9 Europe)
Age ≥ 21, Critically Ill,
AKI (KDIGO Stage 2 or 3)
N = 364
33 patients excluded
21 with insufficient sample volume
9 with invalid test results
2 with HIV or active hepatitis
1 withdrew consent
Analysis Cohort
N = 331
Fig. 1 Patient flow diagram. After exclusions, 331 patients with urinary CCL14 results were available for analysis. 110 patients met the persistent 
severe AKI endpoint (at least 72 consecutive hours of stage 3 AKI, initiation of dialysis, or death following stage 3 AKI)
protein 1 (CHI3L1), plasma cystatin C, urinary liver fatty 
acid binding protein (L-FABP), urinary kidney injury 
molecule-1 (KIM-1)] or with antibody pairs from R&D 
Systems (Minneapolis, MN, USA) [glutathione S-trans-
ferase-pi (GST-pi), interleukin-18 (IL-18)]. Creatinine 
was measured by LabCorp (Burlington, North Carolina, 
USA) using the Jaffe method in serum collected at the 
same time as urine and plasma collected for biomarker 
measurements.
Statistical analysis
A sample size of at least 300 patients was selected to 
achieve a half-width of the 95% CI ≤ 0.05 for the ROC 
AUC, providing a sufficiently narrow CI to assess bio-
marker efficacy. Continuous and categorical baseline 
variables were compared between endpoint negative 
and positive patients using the Wilcoxon rank-sum test 
and Fisher’s exact test, respectively. Predictive ability of 
the biomarkers, including all combinations of two and 
three biomarkers (novel or previously described), for the 
Table 1 Baseline patient characteristics for all patients and by AKI persistence status
a As determined by retrospective analysis
All patients Not persistent severe AKI Persistent severe AKI p value
Patients 331 221 110
Male 207 (62.5%) 136 (61.5%) 71 (64.5%) 0.631
Age (years) 64 (55–73) 64 (54–73) 64 (55–71) 0.636
Body mass index (kg/m2) 29 (25–35) 30 (26–36) 28 (25–34) 0.013
Race 0.371
 Black or African American 34 (10.3%) 26 (11.8%) 8 (7.3%)
 Other/unknown 17 (5.1%) 10 (4.5%) 7 (6.4%)
 White or caucasian 280 (84.6%) 185 (83.7%) 95 (86.4%)
Chronic comorbidities
 Chronic kidney disease 58 (17.5%) 36 (16.3%) 22 (20%) 0.444
 Diabetes mellitus 109 (32.9%) 82 (37.1%) 27 (24.5%) 0.025
 Congestive heart failure 74 (22.4%) 51 (23.1%) 23 (20.9%) 0.677
 Coronary artery disease 117 (35.3%) 84 (38%) 33 (30%) 0.179
 Hypertension 226 (68.3%) 154 (69.7%) 72 (65.5%) 0.454
 Chronic obstructive pulmonary disease 55 (16.6%) 35 (15.8%) 20 (18.2%) 0.639
 Cancer 84 (25.4%) 57 (25.8%) 27 (24.5%) 0.894
Reason for ICU admission
 Respiratory 95 (28.7%) 62 (28.1%) 33 (30%) 0.797
 Surgery 105 (31.7%) 74 (33.5%) 31 (28.2%) 0.381
 Cardiovascular 148 (44.7%) 96 (43.4%) 52 (47.3%) 0.558
 Sepsis 74 (22.4%) 49 (22.2%) 25 (22.7%) > 0.999
 Neurological 16 (4.8%) 12 (5.4%) 4 (3.6%) 0.593
 Trauma 7 (2.1%) 6 (2.7%) 1 (0.9%) 0.432
 Other 107 (32.3%) 74 (33.5%) 33 (30%) 0.536
Vasopressors 210 (63.4%) 139 (62.9%) 71 (64.5%) 0.809
Diuretics 178 (53.8%) 114 (51.6%) 64 (58.2%) 0.293
Fluid balance (mL) 3271 (1267–6422) 2962 (1082–6028) 3768 (1852–7353) 0.037
Days from ICU admission to enrollment 1.1 (0.7–2.2) 1.1 (0.7–2.4) 1.2 (0.7–1.9) 0.990
Mechanical ventilation 185 (55.9%) 121 (54.8%) 64 (58.2%) 0.560
Baseline serum creatinine (mg/dL) 1 (0.8–1.2) 1 (0.8–1.2) 1 (0.8–1.3) 0.083
Enrollment serum creatinine (mg/dL) 2.4 (1.7–3.3) 2.1 (1.5–2.8) 3.4 (2.6–4.2) < 0.001
Enrollment KDIGO  Stagea < 0.001
 No AKI 14 (4.2%) 14 (6.3%) 0 (0%)
 Stage 1 39 (11.8%) 39 (17.6%) 0 (0%)
 Stage 2 168 (50.8%) 129 (58.4%) 39 (35.5%)
 Stage 3 110 (33.2%) 39 (17.6%) 71 (64.5%)
Enrollment non‑renal APACHE III score 54 (43–71) 53 (41–69) 58 (45–82) 0.017
primary endpoint of persistent severe AKI was assessed 
using the area under the receiver operating characteristic 
(ROC) curve. Confidence intervals of the area under the 
ROC curve (AUC) and pair-wise comparisons of AUC 
were calculated by the Delong method. Occurrence of 
 MAKE90 was compared across CCL14 tertiles using the 
Cochran-Armitage test. The cumulative incidence curves 
for the composite of RRT initiation or death were esti-
mated by the Kaplan–Meier method, and log-rank test 
was used to compare the groups. Statistical analyses were 
performed using R 3.5.1. Two-sided p values < 0.05 were 
considered statistically significant. To examine whether 
CCL14 improved risk prediction beyond clinical vari-
ables alone, a reference multiple logistic regression model 
was constructed (Supplement) with those clinical vari-
ables significantly associated with the primary endpoint 
and further selected by a LASSO procedure. Integrated 
discrimination improvement (IDI) and category-free net 
reclassification improvement (cfNRI) were calculated 
with the “Hmisc” R package to assess the enhancement of 
risk prediction by the addition of CCL14 [15].
Results
364 patients were enrolled in the RUBY study, of 
whom  331 (91%) were available for the primary analy-
sis (Fig.  1). Approximately one-third (110 patients) of 
the analysis cohort met the primary endpoint of persis-
tent stage 3 AKI, of whom 56 (51%) received RRT and 
14 (13%) died prior to achieving 72 consecutive hours 
at stage 3. 113 patients (34%) met urine output criteria, 
218 patients (66%) met serum creatinine criteria, and 
53 (16%) patients met both criteria for stage 2–3 AKI at 
enrollment, with 45 (40%), 103 (47%), and 38 (72%) meet-
ing the primary endpoint, respectively. Patients who 
developed persistent stage 3 AKI had a lower BMI and 
were less likely to have a history of diabetes mellitus but 
had higher serum creatinine values, fluid balance, and 
APACHE III scores at enrollment compared to patients 
who did not develop persistent stage 3 AKI (Table  1). 
Patients who developed persistent stage 3 AKI were more 
likely to have stage 3 AKI at enrollment (64.5% vs 17.6%, 
p < 0.001) which is consistent with higher enrollment lev-
els of serum creatinine. Additionally, 128 (39%) patients 
met the secondary  MAKE90 endpoint, of whom 108 
(84%) were deceased, 13 (10%) had ≥ 25% loss in eGFR, 
and 7 (5%) were on dialysis at 90 (± 7) days.
Of the biomarkers tested in this study, urinary C–C 
motif chemokine ligand 14 (CCL14) was most predic-
tive of persistent stage 3 AKI with an AUC (95% CI) of 
0.83 (0.78–0.87), which was significantly greater than 
the AUC values for the other biomarkers tested (Fig.  2 
and Table  S1). Urinary CHI3L1 [16], plasma cystatin 
C, plasma proenkephalin, urinary NGAL, and urinary 
L-FABP had AUC values between 0.70 and 0.75 (Fig. 2). 
Combinations of CCL14 with the other biomarkers did 
not significantly improve the AUC, with the exception 
of plasma cystatin C (AUC increase = 0.028, p = 0.04) 
(Table S2). For all biomarkers associated with AKI, con-
centrations increased with AKI stage (Fig.  3). Among 
patients who did not persist at any stage of AKI, the uri-
nary CCL14 concentrations within different comorbid 
conditions were similar suggesting urinary CCL14 eleva-
tions were specific to AKI persistence. Of note, the other 
AKI biomarkers in Fig. 3 showed substantial elevations in 
patients with some comorbid conditions even if they did 
not have persistent AKI.
Incidence of  MAKE90 was 29%, 40%, and 47%, respec-
tively, within the first, second, and third tertiles of 
CCL14 concentrations (p = 0.01). Mortality at 90  days 
also increased across CCL14 tertiles (p = 0.03), but the 
dialysis and eGFR loss components of  MAKE90 did not 
significantly increase across CCL14 tertiles (Table  S6). 
Cumulative incidence of the composite endpoint of RRT 
initiation or death within 90  days also increased across 
CCL14 tertiles (p < 0.001), approximately doubling from 
32 to 63% for the first to third tertile (Fig. 4). Most events 
(91%) occurred within the first 30 days after enrollment. 
The largest component of  MAKE90 was mortality, which 
occurred in 108 (84%) of patients.
Whether CCL14 enhances predictive ability over clini-
cal variables was tested in a logistic regression model. 
Urinary CCL14 significantly improved risk prediction 
when added to a five-parameter clinical model for the 
Fig. 2 Area under the ROC curve (AUC) for prediction of persistent 
stage 3 AKI by urine CCL14 and other AKI biomarkers, including both 
injury and functional biomarkers. Biomarker concentrations were 
measured in urine and plasma samples collected at enrollment. The 
AUC for urine CCL14 was significantly (p < 0.05) greater than for all 
other biomarkers shown
primary endpoint, using ROC AUC, integrated discrimi-
nation improvement (IDI), and category-free net reclas-
sification improvement (cfNRI) analyses (Tables S3 and 
S4). All analyses showed significant enhancement by the 
addition of CCL14 which remained strongly associated 
with the primary endpoint.
A sensitivity analysis on the definition of AKI per-
sistence demonstrated consistent performance of 
CCL14 across persistence durations of 24, 48, 72, 96, 
and 120 h and progression windows of 24, 48, and 
72 h (Table S5). The ROC AUC (95% CI) ranged from 
0.79 (0.74–0.84) for 24 h persistence and progression 
within 24 h to 0.84 (0.79–0.88) for 48 h persistence and 
progression within 48 h. Moreover, a sensitivity analy-
sis in which the 53 patients retrospectively determined 
not to be at KDIGO stage 2–3 at enrollment (Table 1) 
were excluded showed nearly no change in the results 
for the primary endpoint [AUC (95% CI) = 0.81 (0.76–
0.86)]. Among the patients not at KDIGO stage 2–3 at 
enrollment, 37 (70%) decreased from stage 2–3 by the 
time of enrollment, 10 (19%) were determined to have 
a lower KDIGO stage after adjudication of baseline 
serum creatinine, and 6 (11%) did not meet KDIGO 
criteria at any time.
Discussion
We have shown in a large international cohort of surgical 
and medical intensive care patients that several candidate 
molecules predict persistence of AKI, but that the best 
performing is a previously unknown candidate, urinary 
CCL14. Given this performance, we posit that CCL14 
could be an important mediator of renal tissue damage 
and non-recovery. This is the first time such a finding has 
been described in AKI and the potential implications are 
considerable both for clinical management of patients 
with AKI and potential advancement of our understand-
ing of the mechanism and potential therapeutic targets in 
AKI.
The results of the RUBY study have potential to be 
directly translatable to the clinical management of 
patients. A diagnostic test based on CCL14 which pro-
vides evidence of AKI persistence would aid in determin-
ing which patients may ultimately require RRT and which 
patients are likely to recover quickly and thus are unlikely 
to benefit from RRT initiation. Second, individuals high-
lighted as high risk for AKI persistence may be triaged 
to a referral center or to a higher level of care to miti-
gate potential complications of AKI, including emergent 
RRT. Third, identification of AKI persistence may allow 
for interventions to mitigate the important transition to 
CKD [5].
Our results may help to advance the understand-
ing of the mechanism of AKI and in particular path-
ways related to tissue damage and non-recovery of 
renal function. AKI is associated with renal inflamma-
tion and during this process, circulating monocytes are 
recruited, become activated and differentiate into mac-
rophages. Both glomerular and interstitial macrophage 
infiltration can be observed following injury and mac-
rophages seem to play a diverse role in kidney damage 
and repair [17]. Indeed, in response to tissue injury, 
macrophages become activated with the functional state 
of the macrophage depending on the stage of tissue 
injury and repair. Therefore macrophages may contrib-
ute both to tissue injury and repair after AKI [18]. Such 
macrophage polarization is dictated by the immediate 
microenvironment and appears to play a critical role in 
the recovery of renal function after AKI.
CCL14 is a member of the chemokine family of small 
molecules that were initially recognized for roles in leu-
kocyte chemotaxis and are implicated in tissue injury 
and repair processes. CCL14 binds with high affin-
ity to the chemokine receptors CCR1 and CCR5 and 
lower affinity to CCR3 [19]. CCL14 has been shown to 
be an important chemokine for monocyte/macrophage 
recruitment and is associated with pro-inflammatory 
chemotaxis in a variety of diseases including rheuma-
toid arthritis, multiple sclerosis, and lupus [20, 21]. Lit-
tle is known regarding the role and nature of CCL14 in 
AKI, presumably because CCL14 is not expressed in 
mice and rats, so cannot be studied in pre-clinical mod-
els using these animal models. However, because mac-
rophage recruitment and polarization are believed to 
play important roles in kidney tissue damage and devel-
opment of persistent kidney dysfunction [17], a putative 
role for CCL14 can be proposed (Fig.  5). In addition, 
CCL14 has been shown to be an inflammatory marker 
identifying the risk of developing end-stage renal dis-
ease in diabetics [22].
This proposed mechanism may explain the association 
of elevated levels of CCL14 with persistence of severe 
AKI and non-recovery. The amount of CCL14 secreted 
(See figure on next page.)
Fig. 3 Biomarker concentrations for different non‑AKI acute and chronic conditions and by severity of persistent AKI for a urine CCL14, b urine 
CHI3L1, c plasma cystatin C, d plasma proenkephalin, e urine NGAL, and f urine L‑FABP. Open boxes are for different acute and chronic conditions 
among patients who did not persist at any stage of AKI. Shaded boxes are for patients by persistent AKI stage. Box and whiskers show interquartile 
ranges and total observed ranges (censored by 1.5 times the box range), respectively

could reflect the extent of tissue damage. Moreover, 
higher levels of CCL14 may result in the recruitment of 
larger numbers of monocytes and T-cells which, in a pro-
inflammatory injurious environment, can differentiate 
into  M1 macrophages and Th1 cells that are pathogenic 
and can extend and magnify tissue damage. CCL14 could 
thus provide novel diagnostic and prognostic informa-
tion that is important for managing patients with AKI, 
including decisions related to initiation of RRT. These 
assertions remain speculative and will require further 
investigation.
Our study has several strengths. First, this was an inter-
national multi-center trial that used the latest consen-
sus guidelines to define the stage of AKI and persistent 
dysfunction [5, 10]. Second, all investigators and study 
personnel were unaware of the biomarker test results 
which were batched and measured centrally. Third, we 
measured a broad range of candidate kidney biomarkers 
in this study. Our study also has limitations. For exam-
ple, the type of AKI (nephrotoxic, inflammatory, versus 
septic) was not adjudicated thus performance of various 
biomarkers may differ in subsets of AKI. In addition, the 
secondary outcome variable,  MAKE90, was largely driven 
by mortality and the study had low inclusion to screening 
ratio. Lastly, the study had a small proportion of patients 
who were misclassified at enrollment.
In summary, our findings demonstrate that an eleva-
tion in urinary CCL14 predicts the persistence/pro-
gression of AKI in a large cohort of mixed critically ill 
patients with severe AKI. Consistent with pre-clinical 
studies, chemokine signaling and macrophage traffick-
ing appear to play an important role in renal repair and 
recovery. Discovery of CCL14 as predictor of persistent 
Fig. 4 Composite of RRT initiation or death for patients stratified 
by urine CCL14 tertile. Development of the composite endpoint 
increased across tertiles, log‑rank p < 0.001
AKI and thus, renal non-recovery may not only directly 
affect treatment options in the acute phase but offers the 
potential to identify new therapeutic approaches to AKI.
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